SUSTOL maintains therapeutic levels of granisetron for ≥5 days1

Graph displaying therapeutic levels of granisetron. Levels were reached rapidly after administration and were maintained for ≥5 days.
  • Based on pharmacokinetic data collected from SUSTOL clinical trials.
  • Following a single subcutaneous injection of SUSTOL in 142 healthy volunteers, granisetron was released from the polymer depot by controlled hydrolysis and diffusion over a period of 5 or more days.1
  • Therapeutic levels of granisetron were reached rapidly after administration and were maintained for more than 5 days1
With extended-release delivery, SUSTOL provides protection during both the acute and delayed phases of CINV1
CINV=chemotherapy-induced nausea and vomiting.

References:

  1. SUSTOL [prescribing information]. Heron Therapeutics, Inc., 2017.
  2. Howell et al. J Oncol Pharm Pract. 2009.
  3. Schnadig et al. Future Oncol. 2016.
  4. Zhou et al. Ther Clin Risk Manag. 2015.